US Tariffs on Pharmaceutical Products from China — 35% (2026)
Tariff Rate Breakdown
Pharmaceutical Products from China represent an important segment of bilateral trade, with approximately $575B in total bilateral trade.
The current tariff framework for pharmaceutical products from China reflects the post-SCOTUS landscape: a 10% Section 122 tariff replaced the previously higher IEEPA rates after the Court's February 2026 ruling.
The Section 122 tariff is subject to a 150-day statutory time limit and is set to expire approximately July 24, 2026, unless Congress acts to extend or replace it. Importers should monitor legislative developments closely as this deadline approaches.
Pharmaceutical Products from China are also subject to Section 301 tariffs, which range from 25% to 100% depending on the specific product classification. Section 301 tariffs were not affected by the Supreme Court ruling and remain in full effect. Combined with the Section 122 base rate, importers may face effective rates of 35% or more.
Key products in HTS Chapter 30 imported from China include Vaccines, Antibiotics, Insulin, Bandages, Diagnostic reagents, and Blood products.
Common Products in Chapter 30
Calculate Your Import Duty
Use our tariff calculator to estimate the exact duty on your pharmaceutical products imports from China.
Open Tariff CalculatorFrequently Asked Questions
What is the current tariff rate on pharmaceutical products from China?
Will the tariff on pharmaceutical products from China change?
How did the Supreme Court ruling affect pharmaceutical products imports from China?
Related Pages
Tariff rates change fast. Stay ahead.
Free alerts when US import tariff rates change. Join importers and trade professionals who stay informed.
No spam. Unsubscribe anytime.